MA55219A - Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral - Google Patents

Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral

Info

Publication number
MA55219A
MA55219A MA055219A MA55219A MA55219A MA 55219 A MA55219 A MA 55219A MA 055219 A MA055219 A MA 055219A MA 55219 A MA55219 A MA 55219A MA 55219 A MA55219 A MA 55219A
Authority
MA
Morocco
Prior art keywords
capsid
free
viral dna
lipid nanoparticles
active lipid
Prior art date
Application number
MA055219A
Other languages
English (en)
Inventor
Matthew Manganiello
Matthew G Stanton
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of MA55219A publication Critical patent/MA55219A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA055219A 2019-03-06 2020-03-06 Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral MA55219A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814460P 2019-03-06 2019-03-06
US201962857557P 2019-06-05 2019-06-05

Publications (1)

Publication Number Publication Date
MA55219A true MA55219A (fr) 2022-01-12

Family

ID=72337571

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055219A MA55219A (fr) 2019-03-06 2020-03-06 Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral

Country Status (8)

Country Link
US (1) US20220175968A1 (fr)
EP (1) EP3934700A4 (fr)
AU (1) AU2020232790A1 (fr)
CA (1) CA3131130A1 (fr)
IL (1) IL286026A (fr)
MA (1) MA55219A (fr)
SG (1) SG11202109426YA (fr)
WO (1) WO2020181168A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108728491B (zh) * 2018-06-21 2022-08-26 陕西杆粒生物科技有限公司 一种广谱抗凋亡杆状病毒表达载体
JP2023535632A (ja) * 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
JP7846677B2 (ja) * 2020-09-11 2026-04-15 アルデブロン，エル．エル．シー． 筋特異的ハイブリッドプロモーター
WO2022140788A1 (fr) * 2020-12-23 2022-06-30 Spark Therapeutic, Inc. Procédés pour améliorer la thérapie génique non virale
CA3211687A1 (fr) * 2021-03-19 2022-09-22 Ozan ALKAN Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents therapeutiques de pfic
US20240263195A1 (en) * 2021-05-11 2024-08-08 Modernatx, Inc. Non-viral delivery of dna for prolonged polypeptide expression in vivo
CA3221454A1 (fr) * 2021-06-07 2022-12-15 Michelle LEBLANC Compositions de nanoparticules lipidiques modifiees par apolipoproteine e et apolipoproteine b et utilisations associees
WO2023069948A1 (fr) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vii, Llc Compositions d'adn et procédés associés
US20260115316A1 (en) * 2022-03-28 2026-04-30 Nof Corporation Lipid nanoparticles for delivering nucleic acid to splenic tissue, and method for delivering nucleic acid to splenic tissue using same
JP2025535114A (ja) * 2022-10-11 2025-10-22 メイラグティーエックス ユーケー アイアイ リミティド 中枢神経系における遺伝子発現のための核酸調節エレメント及び使用方法
WO2025007024A1 (fr) * 2023-06-29 2025-01-02 Repertoire Immune Medicines, Inc. Particules lipidiques pour l'administration d'une charge utile
WO2025090138A1 (fr) * 2023-10-24 2025-05-01 Generation Bio Co. Compositions de nanoparticules lipidiques furtives pour le ciblage cellulaire
WO2025090417A1 (fr) 2023-10-24 2025-05-01 Generation Bio Co. Compositions de nanoparticules lipidiques furtives bispécifiques pour le ciblage cellulaire
US20250255985A1 (en) * 2024-02-12 2025-08-14 Modex Therapeutics, Inc. Parvovirus itr-based gene delivery vector system

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745596B2 (en) * 2004-07-12 2010-06-29 Japan Science And Technology Agency Nuclear transport nucleic acid delivery vector
CA2721183C (fr) * 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Delivrance specifique a un site d'acides nucleiques en combinant des ligands de ciblage avec des composants endosomolytiques
JP5860874B2 (ja) * 2010-06-22 2016-02-16 デエヌア・テラプーティックＤｎａｔｈｅｒａｐｅｕｔｉｃｓ 核酸コンジュゲートのためのエンドソーム溶解剤を用いた最適化ｉｎｖｉｖｏ送達システム
WO2016201450A2 (fr) * 2015-06-11 2016-12-15 University Of Miami Traitement et diagnostic du cancer
MX2018010633A (es) * 2016-03-03 2019-06-13 Univ Massachusetts Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral.
EP4653536A3 (fr) * 2017-03-17 2026-02-25 Adverum Biotechnologies, Inc. Compositions et procédés pour une expression génique améliorée

Also Published As

Publication number Publication date
SG11202109426YA (en) 2021-09-29
IL286026A (en) 2021-10-31
US20220175968A1 (en) 2022-06-09
CA3131130A1 (fr) 2020-09-10
EP3934700A4 (fr) 2022-12-14
EP3934700A1 (fr) 2022-01-12
WO2020181168A1 (fr) 2020-09-10
WO2020181168A8 (fr) 2020-10-01
AU2020232790A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
MA55219A (fr) Nanoparticules lipidiques non actives avec adn dépourvu de capside, non viral
EP3947700A4 (fr) Virus adéno-associé comprenant une capside modifiée
IL271389A (en) Targeted non-viral dna insertions
IL272799A (en) Lipid nanoparticle formulations of non-viral capsid-free DNA vectors
MA52709A (fr) Administration d'adn
EP3423110A4 (fr) Adn double hélice linéaire à extrémité fermée pour transfert de gène non viral
EP3186375A4 (fr) Nouvelles protéines cas9 et éléments de guidage pour le ciblage de l'adn et l'édition du génome
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
DK3911354T5 (da) AVV-formidlet genterapi, der genskaber otoferlin-genet
MA40924A (fr) Cathéter avec ensembles d'électrodes empilés
PE20150163A1 (es) Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav
EP2861737A4 (fr) Ciblage de gène dans des plantes à l'aide de virus à adn
EP4055034A4 (fr) Polypeptides de capside virale
EP4055030A4 (fr) Polypeptides de capside virale
JP2014510253A5 (fr)
HK40064224A (en) Non-active lipid nanoparticles with non-viral, capsid free dna
HOCKNEY Drawings
Catrileo et al. PORNOMISERY
Boruch DRAWINGS
Placental Clinical Implications
Banda La faceta axiológica de la dicha personal
李玉峰 Sonoco Product
UA40375S (uk) Тачка будівельна
王志刚 Marty's Birthday Gift
郭铃 Récit à la voix de MARGUERITEDURAS